March 4, 2007

Antiretroviral Resistance Testing In HIV Infected Patients Improves Health And Saves Costs

During HIV treatment resistance mutations of the virus to antiretroviral drugs may occur and the treatment regimen become less effective. In the present study the authors compared the cost-effectiveness of genotypic antiretroviral resistance testing versus expert opinion for treatment optimization in HIV infected patients with treatment failure. The study is based on data from the Swiss HIV Cohort Study (http://www.shcs.ch/), which is one of the largest cohort studies on HIV disease including patients from all University Clinics and two state hospitals in Switzerland. In this study, both health care costs and productivity costs, i.e. costs due to absence from work because of ill-health, were included in the analysis. Using most recent scientific methods, the authors could show that antiretroviral resistance testing not only increases life expectancy and quality-of-life, but also results in cost savings to society.

"This is the first study that shows that resistance testing not only improves the health of the patients but is also beneficial to the society at large when job productivity changes are considered," said Pedram Sendi, first author and principal investigator, from the Clinic of Infectious Diseases & Hospital Epidemiology of the Basel University Hospital. "We are convinced that our study will be noticed in many countries as it also documents the clinical benefit of antiretroviral resistance testing," comment Manuel Battegay from the Basel University Hospital and Huldrych GГјnthard from the Zurich University Hospital, co-principals of this cost-effectiveness study.

In times of increasing pressures to contain health care costs cost-effectiveness analyses are an important source of information to evaluate whether health interventions represent "value for money." This may help to prioritize resource allocation in health care by finding those health technologies that offer the most health outcomes for the resources invested. To date the Swiss HIV Cohort Study has conducted several cost-effectiveness analyses and has contributed to a better understanding of important cost-effectiveness issues in HIV disease.

###

Disclaimer

The above press release refers to an upcoming article in PLoS ONE. The release has been provided by the article authors and/or their institutions. Any opinions expressed in these releases or articles are the personal views of the contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

The study was funded mainly by the Swiss Science National Foundation.

PLoS ONE features reports of primary research from all disciplines within science and medicine. http://www.plosone.org/.

Citation: Sendi P, GГјnthard HF, Simcock M, Ledergerber B, SchГјpbach J, et al (2007) Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE 2(1): e173. doi:10.1371/journal.pone.0000173

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pone.0000173

Contact: Pedram Sendi
Public Library of Science

No comments: